DBV Technologies S.A.

DBVT Nasdaq CIK: 0001613780

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation France
Business Address 107 AVENUE DE LA REPUBLIQUE, CHATILLON, I0, 92320
Mailing Address 107 AVENUE DE LA REPUBLIQUE, CHATILLON, I0, 92320
Phone 33(0)155427878
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025 FY

$5.64M
Revenue
$233.72M
Total Assets

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 26, 2026 View on SEC
10-K Annual financial report March 26, 2026 View on SEC
8-K Current report of material events March 2, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 17, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 13, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 13, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 3, 2026 View on SEC
4 Insider stock transaction report February 2, 2026 View on SEC

Annual Reports

10-K March 26, 2026
  • Successfully completed patient enrollment for the VITESSE Phase 3 clinical trial.
  • Clear roadmap for FDA approval submissions in 2026 for children aged 1–7.
View Analysis

Insider Trading

STRONG SELL 2 insiders 6 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.